← All stories
Markets
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.
Covered by 1 outlet
All coverage · 1 article